ACIB GMBH

Their core work

ACIB (Austrian Centre of Industrial Biotechnology) is a research centre specializing in industrial biocatalysis, enzyme engineering, and bioprocess development. They develop microbial and enzymatic production systems for fine chemicals, biotherapeutics, and bio-based materials — translating laboratory biotechnology into industrially viable manufacturing processes. Their work spans from designing cell factories and biocatalytic cascades to downstream processing and continuous biomanufacturing, serving sectors from cosmetics and nutrition to plastics recycling and CO2 conversion.

What they specialise in

How they've shifted over time

In the early period (2015–2018), ACIB focused on foundational biocatalysis and specific application domains: yeast genetics, carbohydrate chemistry for cosmetics and nutrition, oxidative biocatalysts, and even nano-targeted cancer therapy (NEOSETAC). From 2019 onward, their portfolio shifted decisively toward sustainability applications — enzymatic plastic recycling, CO2 bioconversion, bio-based packaging materials — while also expanding into science communication and public engagement. This evolution reflects a strategic pivot from pure industrial biotechnology toward circular economy and green chemistry applications.

ACIB is moving from traditional industrial enzyme work toward enzymatic solutions for plastic waste, CO2 utilization, and sustainable bio-based materials — positioning themselves at the intersection of biotechnology and circular economy.

How they like to work

ACIB operates primarily as an active participant (12 of 18 projects) but has proven coordination capability, leading 5 projects including substantial ones like CARBAFIN (EUR 1.57M). With 200 unique consortium partners across 25 countries, they are a well-connected hub rather than a repeat-partner organization. Their strong presence in MSCA training networks (6 projects) signals they are valued for doctoral training and knowledge transfer, making them a reliable partner who invests in building research capacity.

ACIB has built an extensive European network of 200 unique partners across 25 countries, reflecting broad connectivity rather than regional clustering. Their heavy involvement in Marie Curie training networks has likely been a major driver of this wide partner base.

What sets them apart

ACIB bridges the gap between academic enzyme research and industrial-scale bioprocessing — a rare combination for an SME-classified research centre. Their dual strength in upstream biology (enzyme engineering, cell factory design) and downstream process engineering (continuous manufacturing, regulatory compliance) means they can take a biocatalytic concept from lab proof to production-ready process. Their recent pivot into enzymatic plastics recycling and CO2 conversion makes them particularly relevant for companies seeking bio-based alternatives to chemical manufacturing.

Highlights from their portfolio

• CARBAFIN
  Largest single grant (EUR 1.57M) and coordinator role — building a platform cell factory for carbohydrate-based fine chemicals across cosmetics, detergents, and nutrition.
• ConCO2rde
  Coordinator of a training network on CO2 bioconversion using synthetic biology — signals their strategic direction toward carbon-negative biotechnology.
• ENZYCLE
  Applies their enzyme expertise to a high-impact sustainability challenge: enzymatic recycling of non-recyclable plastic fractions including multi-layer plastics and microplastics.